Wells Fargo Corporate & Investment Banking, a division of Wells Fargo & Company, announced that Lucy To has joined its Healthcare Coverage group as a managing director focused on

the biotech investment banking sector. Based in New York, To will report to John Fowler, head of Healthcare within the CIB Coverage group.

“To’s appointment further demonstrates Wells Fargo’s commitment to the healthcare/biotechnology sector,” said David Gillespie, head of CIB Coverage at Wells Fargo. “With close to 15 years biotechnology experience, including cross-border expertise in capital raising, mergers and acquisitions, and IPOs, she brings deep industry knowledge and we look forward to her contributions within our Healthcare group.”

To joins Wells Fargo from Deutsche Bank, where she focused on healthcare investment banking coverage of biopharma companies. Prior to that she worked in business development at Intercept Pharmaceuticals and in healthcare investment banking at Citigroup and Cowen.